风险分层和通风器释放在神经脊髓炎光学谱系障碍相关的中枢呼吸道功能衰竭中
Hua Huang1, Yang Liu1, Jiaxin Li1
1Department of Neuro-Intensive Care Unit, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Neurocritical care
|March 12, 2026
概括
血小板-淋巴细胞比率升高和骨髓病变是神经髓炎光学谱系障碍中中枢呼吸系统衰竭的关键危险因素. 大多数患者在早期治疗和对BMI和AQP4-IgG状态等因素的监测的指导下,成功实现了呼吸机释放.
科学领域:
- 神经学 神经学
- 呼吸系统医学 呼吸系统医学
- 免疫学 免疫学 免疫学
背景情况:
- 神经脊髓炎光学谱系障碍 (NMOSD) 可能导致中枢呼吸系统衰竭 (CRF).
- 确定机械通风释放的CRF风险因素和预测因素对于患者管理至关重要.
研究的目的:
- 在NMOSD患者中识别CRF的危险因素.
- 在NMOSD患有CRF的患者中研究机械呼吸器释放成功的预测因素.
主要方法:
- 280名NMOSD患者 (2020-2024) 的回顾性队列分析.
- 慢性脊髓炎被定义为由脑干或椎脊髓高部损伤引起的呼吸衰竭.
- 使用多变量考克斯回归和竞争性风险分析.
主要成果:
- 在NMOSD患者中,CRF发病率为10.0%.
- 血小板-淋巴细胞比率 (PLR) 升高和MRI上的骨髓病变是独立的CRF危险因素.
- 75.0%的CRF患者成功实现了呼吸机释放;早期葡萄糖皮质激素治疗和更高的PLR预测成功.
结论:
- 升高的PLR和骨髓病变是NMOSD中CRF的显著预测因素.
- 一个生成的名图有效地分层了CRF风险.
- 成功的呼吸机释放是可行的;建议早期使用葡萄糖皮质激素治疗和监测BMI,AQP4-IgG状态和败血症.
相关概念视频
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Myasthenia Gravis: Diagnostic Tests
2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K


